Lixivaptan: a novel vasopressin receptor antagonist

By Ku Elaine   Nobakht Niloofar   Campese Vito M  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 5, 2009-05 ,pp. : 657-662

Informa Healthcare

Access to resources Recommend Favorite

Inhibition of the vasopressin-enhancing effect on memory retrieval and relearning by a vasopressin V 1 receptor antagonist in mice

By Alescio-Lautier B.   Rao H.   Paban V.   Devigne C.   Soumireu-Mourat B.  

European Journal of Pharmacology, Vol. 294, Iss. 2, 1995-12 ,pp. : 763-770

Elsevier

Access to resources Recommend Favorite

EFFECT OF CONIVAPTAN, A COMBINED VASOPRESSIN V_1a AND V₂ RECEPTOR ANTAGONIST, ON VASOPRESSIN-INDUCED CARDIAC AND HAEMODYNAMIC CHANGES IN ANAESTHETISED DOGS

By Yatsu T.   Kusayama T.   Tomura Y.   Arai Y.   Aoki M.   Tahara A.   Wada K-I.   Tsukada J.  

Pharmacological Research, Vol. 46, Iss. 5, 2002-11 ,pp. : 375-381

Academic Press

Access to resources Recommend Favorite

Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction

By Wada K.-i.   Tahara A.   Arai Y.   Aoki M.   Tomura Y.   Tsukada J.   Yatsu T.  

European Journal of Pharmacology, Vol. 450, Iss. 2, 2002-08 ,pp. : 169-177

Elsevier

Access to resources Recommend Favorite

Vasopressin-induced contraction of uterus is mediated solely by the oxytocin receptor in mice, but not in humans

By Kawamata M.   Mitsui-Saito M.   Kimura T.   Takayanagi Y.   Yanagisawa T.   Nishimori K.  

European Journal of Pharmacology, Vol. 472, Iss. 3, 2003-07 ,pp. : 229-234

Elsevier

Access to resources Recommend Favorite